Tarik Khaznadar Selected Research

Erlotinib Hydrochloride (CP 358,774)

1/2018

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tarik Khaznadar Research Topics

Disease

1	Renal Cell Carcinoma (Grawitz Tumor) 01/2019
1	Hemorrhage 01/2018
1	Hypertension (High Blood Pressure) 01/2018
1	Pain (Aches) 01/2018
1	Proteinuria 01/2018
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018

Drug/Important Bio-Agent (IBA)

2	Bevacizumab (Avastin)FDA Link 01/2019 - 01/2018
1	Sunitinib (Sutent)FDA Link 01/2019
1	B7-H1 AntigenIBA 01/2019
1	atezolizumabIBA 01/2019
1	LigandsIBA 01/2018
1	Acetic Acid (Vinegar)FDA LinkGeneric 01/2018
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	GSK726701AIBA 01/2018
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018
1	Antihypertensive Agents (Antihypertensives)IBA 01/2018

Therapy/Procedure

1	Therapeutics 01/2018